Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
A Phase IIA Open-Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels.
Closed to Accrual with Ongoing Follow-up
Chemotherapy: Systemic, Immunotherapy
Defintions of terms and FAQ about clinical trials.
Heinz Josef Lenz, M.D.
Other Trial Staff:
Ramona Lujan, R.N., Taison Tran, D.M., Khatchik Karakozian, D.M.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.